samedan logo
 
 
 
spacer
home > ebr > autumn 2020 > boston diary – day 144
PUBLICATIONS
European Biopharmaceutical Review

Boston Diary – Day 144

When I wrote my last column, ‘Run for the Roses’, the race for a COVID-19 vaccine was just getting underway. Now, the preliminary reports are coming in almost daily. Multiple projects, featuring diverse technologies, show early and encouraging progress. Large-scale clinical trials will demonstrate how well the different approaches work in large numbers of people. While the candidates apparently do elicit antibodies, one key question is effectiveness. Will the vaccine provide immunity; in what fraction of the population; and for how long? Achieving herd immunity for COVID-19 is estimated to require an immunity rate somewhere between that of flu and measles vaccines – and we still face significant unknowns in production and distribution.

As a time-honoured stop-gap measure, many hospitals throughout the world have turned to convalescent blood plasma for the more serious cases. Anecdotally, it has provided improvement in patient outcomes and did not potentiate cytokine storms. Post hoc analysis of immunoglobulin G quantitation and patient outcomes for matched subjects strongly suggest efficacy. However, donor plasma is a limited commodity. A number of biopharmaceutical companies have launched programmes to develop synthetic antibodies, which can complement vaccine therapy if they can be made cost-effective.

The soothsayer in Shakespeare’s play, Julius Caesar, was on my mind as the COVID-19 pandemic began to spread. The ‘Ides of March’ arrived, and my office started to work from home. In our region, as in many others, our state government provided guidelines for social distancing, business closures – except for essential operations – and other public health measures. The savings in auto mileage and daily commute time did have a certain appeal. Online meetings soon became the new normal. However, the excessive, back-to-back web meetings every morning get a little tedious.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, and an industry consultant with experience in the biotech and biopharma industry.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

- The biotech companies 3P Biopharmaceuticals and Toleranzia collaborate for that MG treatment - MG is an orphan disease which has a major unmet medical need and a large market potential - The drug candidate,TOL2, has already achieved several positive preclinical results
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

 
Industry Events

CPhI Festival of Pharma

5-16 October 2020, Virtual

A virtual gathering for the pharmaceutical industry, the CPhI Festival of Pharma has been created to fill the gap left by in-person events at a time when travel and gatherings are off the cards.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement